ARS Pharmaceuticals (SPRY) Cash & Equivalents (2020 - 2026)

ARS Pharmaceuticals (SPRY) has 7 years of Cash & Equivalents data on file, last reported at $24.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 38.99% year-over-year to $24.3 million; the trailing twelve-month figure through Mar 2026 stood at $24.3 million (down 38.99% YoY), and the FY2025 full-year result was $41.3 million, down 18.69% from the prior year.
• Cash & Equivalents eased to $24.3 million in Q1 2026, from $41.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $234.0 million in Q1 2022 to a low of $24.3 million in Q1 2026.
• A 5-year average of $94.4 million and a median of $59.6 million in 2025 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents soared 250.5% in 2022 and tumbled 70.21% in 2023, its largest moves.
• Tracing SPRY's Cash & Equivalents over 5 years: stood at $210.5 million in 2022, then sank by 66.29% to $71.0 million in 2023, then declined by 28.4% to $50.8 million in 2024, then slipped by 18.69% to $41.3 million in 2025, then tumbled by 41.14% to $24.3 million in 2026.
• Business Quant data shows SPRY's Cash & Equivalents at $24.3 million in Q1 2026, $41.3 million in Q4 2025, and $59.6 million in Q3 2025.